Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

UCB Pharma, Monheim, Germany

5 abstracts

Abstract
A SINGLE DETERMINATION OF C-REACTIVE PROTEIN DOES NOT SUFFICE TO DECLARE A PATIENT WITH A DIAGNOSIS OF AXIAL SPA “CRP-NEGATIVE”
Org: Clinical Immunology and Rheumatology, Amsterdam Rheumatology & Immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, UCB Pharma, Monheim, Germany, UCB Pharma, Slough, United Kingdom,
Abstract
ACHIEVEMENT OF PASDAS LOW DISEASE ACTIVITY AND VERY LOW DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL OVER 4 YEARS AND THE OVERLAP WITH DAPSA AND MDA DISEASE ACTIVITY TARGETS
Org: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States of america, St Vincent’s University Hospital and Conway institute for Biomolecular Research, University College Dublin, Dublin, Ireland, Division of Rheumatology allergy and Immunology, UC San Diego School of Medicine, La Jolla, CA, United States of america, Department of Dermatology, ICahn School of Medicine at Mt Sinai, New York, NY, United States of america,
Abstract
ACHIEVEMENT OF REMISSION OF INFLAMMATION IN THE SPINE AND SACROILIAC JOINTS MEASURED BY MAGNETIC RESONANCE IMAGING (MRI) IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS, AND ASSOCIATIONS BETWEEN MRI AND CLINICAL REMISSION, OVER 96 WEEKS OF TREATMENT WITH CERTOL
Org: Rheumazentrum Ruhrgebiet, Herne, Germany, Department of Medicine, University of Alberta, Alberta, Canada, Academic Medical Center Amsterdam & Atrium Medical Center, Heerlen, Netherlands, Ruhr-University Bochum, Herne, Charité Medical School, Berlin, Germany,
Abstract
ANALYSIS OF THE ASSOCIATION BETWEEN CIGARETTE SMOKING AND CLINICAL RESPONSE TO CERTOLIZUMAB PEGOL TREATMENT IN HUNGARIAN PATIENTS WITH RHEUMATOID ARTHRITIS
Org: University of Debrecen, Faculty of Medicine, Debrecen, Szent György Hospital, Székesfehérvár, Csolnoky Ferenc Hospital, Veszprém, Hungary, Bács-Kiskun County Hospital, Kecskemét, Vaszary Kolos Hospital, Esztergom, Hungary,
Abstract
BIMEKIZUMAB EFFICACY THROUGH 3 YEARS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: LONG-TERM POOLED ANALYSIS FROM BE BRIGHT
Org: UCB Pharma, Morrisville, North Carolina, United States of America, UCB Pharma, Monheim, Germany, UCB Pharma, Colombes, France,